Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the
pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and …

Vilanterol trifenatate (vilanterol) is a novel, long-acting β 2 -adrenoceptor (β 2 -AR) agonist
with 24 h activity. In this study, we describe the preclinical pharmacological profile of vilanterol …

There is a requirement for efficacious and safe medicines to treat diseases with high unmet
need. The resurgence in αv‐RGD integrin inhibitor drug discovery is poised to contribute to …

The αvβ6 integrin plays a key role in the activation of transforming growth factor-β (TGFβ), a
pro-fibrotic mediator that is pivotal to the development of idiopathic pulmonary fibrosis (IPF). …

Galectin-3 is a carbohydrate-binding protein central to regulating mechanisms of diseases
such as fibrosis, cancer, metabolic, inflammatory, and heart disease. We recently found a high …

Rationale: High circulating galectin-3 is associated with poor outcomes in patients with
coronavirus disease (COVID-19). We hypothesized that GB0139, a potent inhaled …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with
poor prognosis and a significant unmet medical need. This study evaluated the safety, …

Activation of muscarinic subtype 3 (M3) muscarinic cholinergic receptors (mAChRs) increases
airway tone, whereas its blockade improves lung function and quality of life in patients …

Purpose Inhaled drug delivery is an attractive route by which to deliver drugs to lungs of
patients with idiopathic pulmonary fibrosis (IPF). GSK3008348 is a potent and selective small …

Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in
acute lung injury (ALI) remains unknown. Effective pharmacological therapies available for ALI …